Sidley Austin represented IDEX Corporation in the transaction, and Cooley represented Mott Corporation. IDEX Corporation (NYSE: IEX) (“IDEX”) announced its acquisition of Mott Corporation, a leading...
You must be a Standard 1 Year member to access this content.
Cooley advised ACELYRIN, and Davis Polk advised the joint book-running managers. ACELYRIN, INC. announced its upsized initial public offering of 34,500,000 shares of common stock at...
You must be a Standard 1 Year member to access this content.
Cooley advised SCYNEXIS on the deal. SCYNEXIS announced its exclusive license agreement with GSK for Brexafemme. The exclusive license agreement gives GSK rights to commercialize SCYNEXIS’ ibrexafungerp...
You must be a Standard 1 Year member to access this content.
Cooley LLP and Matheson LLP advised Horizon, while Sullivan & Cromwell LLP and William Fry LLP advised Amgen. Debevoise & Plimpton LLP advised JP Morgan. Macfarlanes...
You must be a Standard 1 Year member to access this content.
Skadden advised Vertex Pharmaceuticals Incorporated on the deal while Cooley represented ViaCyte. Vertex Pharmaceuticals Incorporated (“Vertex”) has entered into a definitive agreement under which Vertex will acquire...
You must be a Standard 1 Year member to access this content.
Cooley advised Turning Point Therapeutics, while Kirkland & Ellis advised Bristol Myers Squibb on the deal. Bristol Myers Squibb (NYSE:BMY), a global biopharmaceutical company, announced its...
You must be a Standard 1 Year member to access this content.
Cooley and Arendt advised Alvotech Holdings, while Kirkland & Ellis, working alongside Walkers and King & Spalding and Elvinger Hoss Prussen, advised Oaktree Acquisition Corp. II...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz represented IAC, while Cooley represented Meredith in the transaction. IAC (NASDAQ: IAC) and Meredith Corporation (NYSE: MDP), a leading media company...
You must be a Standard 1 Year member to access this content.
Latham & Watkins and Goldfarb Seligman & Co. represented Itamar Medical in the transaction. Cooley and Gornitzky & Co. advised ZOLL Medical. Itamar™ Medical Ltd. (Nasdaq...
You must be a Standard 1 Year member to access this content.
Cooley and Wilson Sonsini Goodrich & Rosati advised Vividion Therapeutics on the deal. Vividion Therapeutics, a biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally...
You must be a Standard 1 Year member to access this content.
